To successfully deliver innovative and life-changing therapies, you need high-quality products and services that push what’s possible and meet regulatory compliance.

That’s where we come in.

We are committed to providing our partners with the flexibility to choose from advanced technology platforms and unique service models to meet specific project needs.

Our off-the-shelf assay-ready reporter gene cell and customized cell development services, in combination with our specialized laboratory services, are ready to discuss the perfect package to assist in your drug development.

Talk to us today!

Meet our Team of Experts! 

Don't miss our Poster Presentations

← Quantification of bispecific antibody-mediated T-cell activation with engineered CD3 effector and tailored target cells
Authors: Ulrich Mayer, Frier Bovin L, Gobbo E, Ferrando-Miguel R, Lallemand C Svar Life Science AB, Malmö, Sweden

Development of a new class of target cell lines to evaluate Fc-mediated Cytotoxicity →
Authors: Michael Schwenkert, Frier Bovin L, Gobbo E, Ferrando-Miguel R, Grygar C, Lallemand C

Potency Testing 

We perform both GMP and non-GMP analysis of Biologics and Biosimilar samples from development and manufacturing. Our services include method development, qualification, validation, and continuous method improvements for early and late development projects.

Our service offerings include testing of drug substances, final products, intermediates, and starting materials for large molecule drug products. In addition, we have a range of potency assays, both cell-based and Ligand bidding, that can be applied.

We can help you develop robust and truly MOA-reflective potency assays to accelerate your drug development.

> Learn more

Functional MOA reflective Cell-Based Assays 

Biological activity is a critical quality attribute for biopharmaceuticals and a functional bioassay will, in many cases, give a more intricate answer than a traditional binding assay since the functionality of the compound can be determined, not just a binding interaction.

• Engineered Cell Lines tailored for challenging bioassays
• Assay Ready Cells format enabling easy workflow and maximized control
• innovative solutions tailored to your assay development and manufacturing needs

Discover the benefits of the iLite^® Technology.

> Learn more

FC-Effector Functions

Discover our suite of ADCC/ACDP and CDC Effector cells.

The iLite Fc Effector Reporter Gene Bioassays Portfolio consists of a range of reporter gene cell lines and antigen-specific target cells that can be used in biologically relevant, MOA-reflective assays to measure the Fc effect of antibodies and other biologics that specifically bind and activate Fc receptors.

In addition to this, and to complete the picture, our newly launched CDC Bioassasy, built upon the same technology, provides a versatile and assay-ready platform to assess antibody-mediated Complement-dependent cytotoxicity (CDC) accurately.

They are all based on a Luciferase reporter gene system and offer a convenient and powerful way of measuring the efficacy of antibodies to elicit ADCC, ADCP and CDC in vitro.

> Learn more

FUNCTIONAL BIOASSAYS

Complement Products

iLite^® C5a [BM4075]

Cytokine responsive

iLite^® RANKL [BM4052]
iLite^® TNF-alpha [BM3044]
iLite^® Type I IFN [BM3049]
iLite^® Type I IFN FAST [BM4049]

Hormone responsive

iLite^® hCG [BM4080]
iLite^® Insulin [BM3060]

Toll-like receptors

iLite^® TLR4 [BM4025]
iLite^® TLR9 [BM6069]

Interleukine responsive

iLite^® IL-2 [BM4002]
iLite^® IL-6 [BM4061]
iLite^® IL-12 [BM4012]
iLite^® IL-23 [BM4023]

Growth Factors

iLite^® VEGF [BM4021]
iLite^® FGF-21 [BM3071]
iLite^® GM-CSF [BM4050]
iLite^® G-CSF [BM4055]

FC EFFECTOR CELLS 

Effector Cells

iLite^® ADCC Effector FcγRIIIa (V) [BM5001]
iLite^® ADCP Effector FcγRIIa [BM5004]

Target Cells

iLite^® CD19 (+) Target [BM5025]
iLite^® CD19 (-) Target [BM5026]
iLite^® CD20 (+) Target [BM5010]
iLite^® CD20 (-) Target [BM5015]
iLite^® EGFR (+) Target [BM5035]
iLite^® EGFR (-) Target [BM5036]
iLite^® HER2 (+) Target [BM5011]
iLite^® HER2 (-) Target [BM5016]
iLite^® mTNF-alpha (+) Target [BM5013]
iLite^® mTNF-alpha (-) Target [BM5014]
iLite^® mVEGF (+) Target [BM5017]
iLite^® mVEGF (-) Target [BM5018]

T-CELL ACTIVATION CELLS 

FUNCTIONAL ASSAYS

Properdin
Complement Factor P Functional Assay [COMPL FPF RUO]

Alternative Pathway
WIESLAB^® Complement Alternative Pathway [COMPLAP330]
WIESLAB^® Complement Alternative Pathway (RUO) [COMPLAP330RUO]

Classical Pathway
WIESLAB^® Complement Classical Pathway [COMPLCP310]
WIESLAB^® Complement Classical Pathway (RUO) [COMPLCP310RUO]

MBL Pathway
WIESLAB^® Complement MBL Pathway [COMPLMP320]
WIESLAB^® Complement MBL Pathway (RUO) [COMPLMP320RUO]

Complement Screen
WIESLAB^® Complement Screen [COMPL300]
WIESLAB^® Complement Screen (RUO) [COMPL300RUO]

BIOMARKER ASSAYS

Complement C4d [COMPL C4d RUO]
Complement TCC [COMPL TCC RUO]
Complement Factor P Quantitative Assay [COMPL FPQ RUO]

CELL-BASED ASSAYS

iLite^® C5a Assay Ready Cells [BM4075]

DOWNLOAD CASE STUDY

Learn more about the process at Svar of designing, constructing, producing and validating a fit-for purpose potency assay for use in batch release of an AAV based gene therapy drug.

• iLite^® Technology, Cell-based Reporter Gene Assays
• Join us as we explore the future of Gene Therapy
• Custom Development Cell-based Services - adapted to your needs

• How functional iLite cells can be used in the quest to find new treatments

Videos

• iLite Technology - Bringing light to your drug development
  
  
• Gene Therapy - Moving from promise to reality in gene therapy
  
  

• Wieslab Bioanalytical Services
  - Answering to the complexities of large molecules

• Complement Therapeutics - Let us guide you on the Complement Pathway